Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages
Version of Record online: 25 MAY 2012
© 2012 The Authors. Psychiatry and Clinical Neurosciences © 2012 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 66, Issue 4, pages 247–260, June 2012
How to Cite
Mansur, R. B., Zugman, A., Asevedo, E. d. M., da Cunha, G. R., Bressan, R. A. and Brietzke, E. (2012), Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry and Clinical Neurosciences, 66: 247–260. doi: 10.1111/j.1440-1819.2012.02354.x
- Issue online: 25 MAY 2012
- Version of Record online: 25 MAY 2012
- Received 5 October 2011; revised 8 November 2011; accepted 27 December 2011.
Aims: In this paper, we review the literature on the efficacy of anti-inflammatory agents as neuroprotectors in clinical and preclinical stages of schizophrenia.
Method: A synthetic and integrative approach was applied to review studies stemming from epidemiology, phenomenology, cognition, genetics and neuroimaging data. We provide conclusions and future directions of research on early-onset schizophrenia.
Results: Abnormal inflammatory activation has been demonstrated in schizophrenia. Increases or imbalances in cytokines before birth or during childhood may impact neurodevelopment and produce vulnerability to schizophrenia. The specificity of inflammatory abnormalities in psychiatric disorders is controversial. Similar increases in pro-inflammatory cytokines have been described in other disorders, especially mood and anxiety disorders. One of the most important challenges at this point is the understanding of neurobiological correlates of prodromal stages of schizophrenia.
Conclusion: Although future research should investigate the exact role of different cytokines in pathophysiology of schizophrenia, these mediators emerge as promising molecular targets to its prevention and treatment.